← Back to patent-cliff list
Vopenfasinib
Tier C — Watch / tradeVopenfasinib
Novita Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Fascin
Indications (approved)：Ovarian cancer, Solid tumour, Small cell lung cancer, Metastatic cancer, Lung cancer, Liver cancer, Colon cancer, Prostate cancer
Regional status
US
Phase III
2025-12-29
EU
-
China
Phase II
2024-09-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vopenfasinib?
Approved indications include: Ovarian cancer, Solid tumour, Small cell lung cancer, Metastatic cancer, Lung cancer, Liver cancer, Colon cancer, Prostate cancer.
When does the Vopenfasinib patent expire?
No public expiry year is available for Vopenfasinib yet; this page updates once verified.
How do I get a quote for Vopenfasinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29